Third SGLT2 inhibitor to be marketed in Canada

Empagliflozin "Jardiance" is the third member of the SGLT2 inhibitor class to be marketed in Canada.Ā  Like the other two members of the class (canagliflozin "Invokana" and dapagliflozin "Forxiga") it…

U.S. FDA warns on SGLT2 inhibitors, a class of type 2 diabetes drugs

This past Friday the US Federal Drug AdministrationĀ released a warning that some newer type 2 diabetes drugs, known as SGLT2 inhibitors, may causeĀ ketoacidosis, orĀ dangerously high levels of blood acids that…